Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

P2Y12抑制剂

  • Home
  • P2Y12抑制剂
Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations
Posted inCardiology news

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

Posted by MedXY By MedXY 02/20/2026
Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.
Read More
  • Obicetrapib’s Impact on Lipoprotein(a) in High Cardiovascular Risk Patients: A Comprehensive Pooled Analysis
  • Sirolimus-Eluting Balloons in Coronary In-Stent Restenosis: Comparative Efficacy Against Repeat DES and Balloon Angioplasty
  • Adolescent Cardiorespiratory Fitness and the Trade-Off Between Atrial Fibrillation Risk and Cardiovascular Benefits: Evidence from a Nationwide Sibling-Controlled Cohort Study
  • Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients
  • Intermittent Theta Burst Stimulation of the Dorsomedial Prefrontal Cortex Enhances Expectancy-Driven Placebo Mood Effects in Depression: Evidence from a Randomized Clinical Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in